Late-appearing PML/RARalpha fusion transcript with coincidental t(12;13)(p13.2;q14) in acute promyelocytic leukemia lacking the t(15;17) cytogenetic anomaly

Cancer Genet Cytogenet. 2000 Jun;119(2):121-6. doi: 10.1016/s0165-4608(99)00233-2.

Abstract

The late appearance of a cytogenetic/molecular hallmark in human leukemias is a rare event. We report on a case of acute myeloid leukemia with morphology, immunophenotype and clinical features typical of promyelocytic subtype (APL), in which the specific PML/RARalpha gene rearrangement was molecularly detected only at second relapse of disease, without cytogenetic evidence of the t(15;17). The emergence of the PML/RARalpha gene may be therapy-related or may represent the exceptional result of a clonal evolution during progression of neoplasia. At second relapse, a novel cell clone bearing a t(12;13)(p13.2;q14) was also observed and a molecular deletion and rearrangement of a locus at 13q14, distinct from retinoblastoma (Rb1) locus, was found. In this unusual case, the PML/RARalpha product seems to be not essential for the expression of the promyelocytic phenotype at diagnosis and, when detectable, it is not the sole genetic defect.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosomes, Human, Pair 12 / ultrastructure*
  • Chromosomes, Human, Pair 13 / ultrastructure*
  • Chromosomes, Human, Pair 15 / ultrastructure
  • Chromosomes, Human, Pair 17 / ultrastructure
  • Clone Cells / pathology
  • Disease Progression
  • Fatal Outcome
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / genetics*
  • Leukemia, Promyelocytic, Acute / pathology
  • Middle Aged
  • Neoplasm Proteins / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • RNA, Messenger / biosynthesis*
  • RNA, Neoplasm / biosynthesis*
  • Recurrence
  • Time Factors
  • Translocation, Genetic*

Substances

  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • RNA, Messenger
  • RNA, Neoplasm
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein